GLAUKOS Corp

Glaukos is an ophthalmic pharmaceutical and medical technology company that develops and sells dropless therapies for glaucoma, corneal disorders, and retinal disease. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and launched its first MIGS device, the iStent, commercially in 2012. In 2024, Glaukos began selling iDose® TR, a long-duration, intracameral procedural pharmaceutical implant that continuously delivers glaucoma drug therapy inside the eye. The company also provides proprietary bio-activated pharmaceutical therapies for corneal disorders. Glaukos's commercial and development-stage solutions for eye care professionals include procedural pharmaceuticals that use intracameral drug delivery to reduce intraocular pressure (IOP) by delivering glaucoma medication from inside the eye over time. They also offer MIGS products, which involve inserting a micro-scale device to reduce IOP by restoring natural aqueous humor outflow for glaucoma patients. Additionally, Glaukos provides bio-activated pharmaceuticals designed to strengthen, stabilize, and reshape the cornea for patients with corneal ectatic disorders like keratoconus, and transdermal pharmaceuticals applied to the eyelid for conditions such as demodex blepharitis and myopia.